Publications by authors named "Ozguel Tap"

DICER1-associated sarcoma is an emerging entity, defined by either somatic or germline dicer 1, ribonuclease III (DICER1) mutations and sharing characteristic morphologic features irrespective of the site of origin. In addition to the DICER1 driver mutation, concurrent genomic alterations, including tumor protein 53 (TP53) inactivation and RAS pathway activation, are frequently detected. Tumors that morphologically resemble malignant peripheral nerve sheath tumor (MPNST) have rarely been reported among DICER1 sarcomas and often pose diagnostic challenges.

View Article and Find Full Text PDF

Purpose: The cancer/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS).

Methods: In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1cT letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01-, HLA-A*02:05-, and/or HLA-A*02:06-positive advanced/metastatic NY-ESO-1-expressing MRCLS. Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR).

View Article and Find Full Text PDF

Background: The clinical frailty scale (CFS) was used as a triage tool for medical decision making during the COVID-19 pandemic. The CFS has been posed as a suitable risk marker for in-hospital mortality in COVID-19 patients. We evaluated whether the CFS is associated with mortality 24 months after hospitalisation for COVID-19.

View Article and Find Full Text PDF

Background: Postoperative complications and extended length of stays (LOS) following lobectomy for non-small cell lung cancer (NSCLC) remain significant healthcare and economic burdens, especially in developing countries with limited resources. This study evaluated the effectiveness of enhanced recovery after surgery (ERAS) protocols in addressing these issues.

Methods: This observational study compared two groups of patients, utilizing a prospective arm for ERAS and a retrospective arm for routine care.

View Article and Find Full Text PDF

Background: Plasma osteopontin (pOPN) is a promising aging-related biomarker among individuals with and without kidney disease. The interaction between sex, pOPN levels, and global and cardiorenal outcomes among older individuals was not previously evaluated.

Methods: In this study we investigated the association of pOPN with 24-month global mortality, major cardiovascular events (MACEs), MACEs + cardiovascular (CV) mortality, and renal decline among older individuals; we also evaluated whether sex modified observed associations.

View Article and Find Full Text PDF

Background/objectives: Titanium dental implants are considered to be the most modern and effective solution for replacing lost teeth. These medical devices not only restore the chewing and aesthetic functionality of the smile but also provide a stable support for crowns, bridges or dentures. The aim of this study was to identify the perceptions of patients about titanium dental implants and their effects on the human body.

View Article and Find Full Text PDF

Purpose: In this study, a comprehensive analysis of costs of chronic kidney disease (CKD) was performed, to understand factors associated with the economic burden of the disease in a multicentre international framework.

Methods: The impact on costs of demographics, socio-economics, clinical, and functional variables was tested in 2204 subjects aged 75 years or more attending outpatient clinics in Europe using a multicentre 2-year prospective cohort study. By means of collected resources consumption and unit cost data a comprehensive cost database was built and then investigated using multilevel regression modeling.

View Article and Find Full Text PDF
Article Synopsis
  • Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
  • It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
  • Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate the relationship between phase angle (PhA), a marker of hydration and nutritional status, and the development of sarcopenia in older adults.
  • It involved 696 participants aged 75 and older, assessing them for sarcopenia and related physical capabilities over 24 months using various tests and methods.
  • While lower baseline PhA was observed in those who developed sarcopenia, it was not confirmed as a significant predictor after accounting for other related factors, raising questions about its practical use as an early marker for sarcopenia risk.
View Article and Find Full Text PDF

Purpose: Survival of patients with metastatic sarcoma remains poor, and there is a pressing need for new therapies. Most sarcoma subtypes are not responsive to immune checkpoint inhibition alone. Lenvatinib, a multireceptor tyrosine kinase inhibitor targeting tumor vasculature, has an immunomodulatory activity that contributes to its antitumor effects.

View Article and Find Full Text PDF
Article Synopsis
  • This phase II study (Alliance A091401) evaluates the effectiveness of nivolumab (N) alone and in combination with ipilimumab (N+I) on patients with different types of sarcomas, focusing on treatment responses and biomarkers.
  • The study involved 66 patients with various sarcoma types, and while neither N nor N+I showed positive responses in gastrointestinal stromal tumors (GIST), N+I had a better response in dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS).
  • Results highlighted that traditional biomarkers did not predict immunotherapy response, but genomic instability markers correlated with better clinical outcomes, emphasizing the need for more research in
View Article and Find Full Text PDF
Article Synopsis
  • Epithelioid hemangioendothelioma (EHE) is difficult to treat with traditional chemotherapy, prompting researchers to explore new therapies such as sirolimus and identify biomarkers for tumor aggressiveness.
  • Scientists created a patient-derived xenograft (PDX) model from an advanced EHE patient to test sirolimus and to study serum levels of Growth/Differentiation Factor 15 (GDF-15) as a potential biomarker.
  • The results indicated sirolimus was more effective than doxorubicin in reducing tumor growth and GDF-15 levels, establishing GDF-15 as a promising biomarker for EHE aggressiveness and potentially indicating the effectiveness of sirolimus in patients.
View Article and Find Full Text PDF
Article Synopsis
  • A retrospective study by the Ultra-Rare Sarcoma Working Group analyzed data from 101 patients with metastatic low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid (H)-LGFMS/SEF across 28 centers from January 2000 to September 2022.
  • The study measured progression-free survival (PFS) from the detection of metastasis and after starting treatment, revealing varying effectiveness among the different sarcoma types and treatments.
  • Findings showed that metastatic LGFMS and SEF had distinct survival outcomes, with systemic treatments showing limited effectiveness, suggesting a need for new therapeutic options in future research.
View Article and Find Full Text PDF

The objective of this study is to develop a multimodal neural network (MMNN) model that analyzes clinical variables and MRI images of a soft tissue sarcoma (STS) patient, to predict overall survival and risk of distant metastases. We compare the performance of this MMNN to models based on clinical variables alone, radiomics models, and an unimodal neural network. We include patients aged 18 or older with biopsy-proven STS who underwent primary resection between January 1st, 2005, and December 31st, 2020 with complete outcome data and a pre-treatment MRI with both a T1 post-contrast sequence and a T2 fat-sat sequence available.

View Article and Find Full Text PDF
Article Synopsis
  • Leiomyosarcomas (LMS) are a type of cancer that can happen by chance or be linked to genetic conditions, and scientists are studying how genetic changes might affect them.
  • In a study of 285 LMS cases, about 27% had harmful genetic changes that could influence the cancer, with most of these changes found in soft tissue LMS.
  • The findings suggest that certain genetic changes are more common in younger patients with soft tissue LMS, and knowing about these genetic changes can help with future testing and treatment plans.
View Article and Find Full Text PDF

Limited guidance exists on streamlining cancer therapy for adolescent and young adult (AYA) patients 15-39 years of age, as much of the current data are extrapolated from pediatric or adult counterparts and can differ significantly between the two care models. Harmonization of standard treatment approaches has the potential to improve outcomes and establish a foundation for the development of future clinical trials. We present our experience harmonizing treatment and supportive care regimens for AYA patients with osteosarcoma receiving treatment with methotrexate, doxorubicin, and cisplatin (MAP) therapy on the pediatric and adult sarcoma services at the Memorial Sloan Kettering Cancer Center.

View Article and Find Full Text PDF
Article Synopsis
  • TGCT is a challenging tumor to treat, primarily managed through surgery, but there are few options for patients who can't have surgery; this study investigates vimseltinib, a new oral medication targeting the CSF1 receptor.
  • Conducted as a phase I/II trial with 69 patients (37 with various malignant tumors and 32 with TGCT), the study aimed to evaluate the safety, tolerability, and pharmacokinetics of vimseltinib, while looking at its potential effectiveness.
  • The results showed that vimseltinib was generally well tolerated with a recommended dose of 30 mg taken twice a week, and achieved a 72% objective response rate in TGCT patients, demonstrating promising
View Article and Find Full Text PDF

Background: Current guidelines recommend use of adjuvant imatinib therapy for many patients with gastrointestinal stromal tumours (GISTs); however, its optimal treatment duration is unknown and some patient groups do not benefit from the therapy. We aimed to apply state-of-the-art, interpretable artificial intelligence (ie, predictions or prescription logic that can be easily understood) methods on real-world data to establish which groups of patients with GISTs should receive adjuvant imatinib, its optimal treatment duration, and the benefits conferred by this therapy.

Methods: In this observational cohort study, we considered for inclusion all patients who underwent resection of primary, non-metastatic GISTs at the Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY, USA) between Oct 1, 1982, and Dec 31, 2017, and who were classified as intermediate or high risk according to the Armed Forces Institute of Pathology Miettinen criteria and had complete follow-up data with no missing entries.

View Article and Find Full Text PDF

Dysregulated epigenetic states are a hallmark of cancer and often arise from genetic alterations in epigenetic regulators. This includes missense mutations in histones, which, together with associated DNA, form nucleosome core particles. However, the oncogenic mechanisms of most histone mutations are unknown.

View Article and Find Full Text PDF

Background: Craniofacial osteosarcomas (CFOS) are uncommon malignant neoplasms of the head and neck with different clinical presentation, biological behavior and prognosis from conventional osteosarcomas of long bones. Very limited genetic data have been published on CFOS.

Methods: In the current study, we performed comprehensive genomic studies in 15 cases of high-grade CFOS by SNP array and targeted next generation sequencing.

View Article and Find Full Text PDF

Purpose: The aim of the present study was to investigate characteristics and outcomes in vaccinated and unvaccinated older patients hospitalized for COVID-19 infection.

Methods: A retrospective multicentre cohort study among patients aged ≥70 years hospitalized for COVID-19 infection.

Results: 263 vaccinated and 82 unvaccinated patients were included.

View Article and Find Full Text PDF

Purpose: Viral mutations and improved prevention or treatment options may have changed the association of frailty with mortality throughout the COVID-19 pandemic. We investigated how associations of frailty with in-hospital mortality changed throughout the pandemic in older people hospitalised for COVID-19.

Methods: The COVID-OLD study included COVID-19 patients aged ≥ 70 years hospitalised during the first (early 2020), second (late 2020), third (late 2021) or fourth wave (early 2022).

View Article and Find Full Text PDF
Article Synopsis
  • Tenosynovial giant cell tumour (TGCT) is a locally aggressive tumor with limited treatment options, leading this study to assess vimseltinib, a CSF1R inhibitor, in patients whose TGCT symptoms prevent surgery.
  • The MOTION trial, a phase 3 randomized study, involved 123 adults from 35 hospitals globally, comparing vimseltinib to a placebo over 24 weeks, focusing on the objective response rate determined by independent radiological review.
  • Results showed a significant objective response rate of 40% for vimseltinib compared to 0% for placebo, with most side effects being mild (grade 1 or 2), highlighting vimseltinib's
View Article and Find Full Text PDF

ALL cures require many MRD therapies. This strategy should drive experiments and trials in metastatic bone sarcomas.

View Article and Find Full Text PDF